Precipio, Inc.
Precipio, Inc. (Nasdaq Capital Market) operates as a healthcare biotechnology company focused on improving cancer diagnostics, particularly in hematologic malignancies. The company's website is www.precipiodx.com. Precipio operates through two complementary business divisions within a single operating segment: a… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Precipio, Inc. does
In the company’s own words
Precipio, Inc. (Nasdaq Capital Market) operates as a healthcare biotechnology company focused on improving cancer diagnostics, particularly in hematologic malignancies. The company's website is www.precipiodx.com. Precipio operates through two complementary business divisions within a single operating segment: a Pathology Services Division and a Products Division.
The Pathology Services Division provides specialized cancer diagnostic testing services to physicians, hospitals, and laboratories, primarily focusing on hematologic cancers through molecular diagnostics, cytogenetics, and advanced laboratory analyses. The division operates two fully equipped clinical laboratories in Connecticut that receive patient samples from oncology practices across more than twenty states. This division generates recurring revenue while serving as an internal clinical environment for product development and validation.
The Products Division develops and commercializes proprietary diagnostic assays designed for use by other clinical laboratories. The company's current product offerings include HemeScreen, a suite of disease-specific genetic diagnostic panels utilizing RT-PCR technology for rapid, cost-effective testing of myeloproliferative neoplasms, acute myeloid leukemia, chronic lymphocytic leukemia, cytopenia, and BCR-ABL mutations, and IV-Cell, a proprietary cell culture media enabling simultaneous culturing of multiple hematopoietic cell lineages to reduce diagnostic errors.
Precipio's integrated operating model leverages its clinical laboratory infrastructure to support research and development activities at reduced cost and accelerated timelines compared to traditional product-focused organizations. The company benefits from direct access to patient specimens, clinical expertise, and real-world feedback that inform product development and validation.
As of March 2026, Precipio employed seventy-one full-time and part-time employees based primarily in Connecticut, with workforce distribution across finance and administration, laboratory and production, sales and marketing, customer service, and research and development functions. The company participates in the United States oncology diagnostic market, which exceeds $116 billion and is estimated to grow at a compound annual growth rate exceeding five percent through 2034.
Company details
- Sector
- Healthcare
- Industry
- Medical Instruments
- Headquarters
- NEW HAVEN, CT
- Fiscal year end
- December
- CIK
- 1043961
- SIC
- 3826
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Precipio, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Precipio, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Precipio, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Precipio, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Precipio, Inc.'s last four quarterly filings that the numbers alone won't show?”